PMID- 31146593
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20240226
IS  - 1525-6014 (Electronic)
IS  - 0148-0545 (Linking)
VI  - 44
IP  - 1
DP  - 2021 Jan
TI  - Protective and anti-inflammatory effect of selenium nano-particles against 
      bleomycin-induced pulmonary injury in male rats.
PG  - 92-100
LID - 10.1080/01480545.2018.1560466 [doi]
AB  - Pulmonary fibrosis (PF) is an interstitial lung disease, in which the exact 
      pathologic mechanisms are not fully understood. Drug trials for the treatment of 
      PF have shown disappointing results and controversial. Recently, selenium 
      nanoparticles (SeNPs) have received great attention for potential use in 
      treatments, due to high bioactivity features and lower toxicity. This study 
      evaluated the protective effect of SeNPs against pulmonary injury induced by 
      bleomycin (single dose, 4 mg/kg, intratracheal) in male rats in early and late 
      phases of the disease. The rats were treated with SeNPs by intraperitoneal 
      injection (0.5 mg SeNP/kg) for five consecutive days in the early phase (a day 
      after injection of bleomycin) and late phase (a week after injection of 
      bleomycin). The results showed that injection of SeNPs in the early phase 
      improved the degree of alveolitis and inflammation and lung structure damage. 
      Also, led to significant decreases in density of transforming growth factor- beta1 
      (TGF-beta1) in the lung and tumor necrosis factor-alpha (TNF-alpha) levels in the serum and 
      lung homogenates compared with bleomycin-administrated group. Notably, treatment 
      with the SeNP during the late phase did not show any ameliorative effects. Thus, 
      the data suggest that SeNP has a protective effect against bleomycin-induced 
      pulmonary injury in rats in the early phase of the disease. This might mean that 
      SeNPs may be a new therapeutic agent for the improvement of this disease in the 
      early phases.
FAU - Shahabi, Rana
AU  - Shahabi R
AD  - Department of Physiology, School of Medicine, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Anissian, Ali
AU  - Anissian A
AD  - Veterinary Pathology Department, Islamic Azad University, Abhar, Iran.
FAU - Javadmoosavi, Seyed Ali
AU  - Javadmoosavi SA
AD  - Air Pollution Center of Iran University of Medical Sciences, Tehran, Iran.
FAU - Nasirinezhad, Farinaz
AU  - Nasirinezhad F
AD  - Physiology Research Center, Department of Physiology, School of Medicine, Iran 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20190531
PL  - United States
TA  - Drug Chem Toxicol
JT  - Drug and chemical toxicology
JID - 7801723
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Selenium Compounds)
RN  - 0 (Tgfb1 protein, rat)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 11056-06-7 (Bleomycin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Bleomycin
MH  - Disease Models, Animal
MH  - Lung/*drug effects/metabolism/pathology
MH  - Male
MH  - *Nanoparticles
MH  - Pneumonia/chemically induced/metabolism/pathology/*prevention & control
MH  - Pulmonary Fibrosis/chemically induced/metabolism/pathology/*prevention & control
MH  - Rats, Wistar
MH  - Selenium Compounds/*pharmacology
MH  - Signal Transduction
MH  - Transforming Growth Factor beta1/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Rats
OTO - NOTNLM
OT  - Pulmonary injury
OT  - bleomycin
OT  - selenium nanoparticles
OT  - transforming growth factor-beta1
OT  - tumor necrosis factor alpha
EDAT- 2019/05/31 06:00
MHDA- 2021/08/04 06:00
CRDT- 2019/06/01 06:00
PHST- 2019/05/31 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
PHST- 2019/06/01 06:00 [entrez]
AID - 10.1080/01480545.2018.1560466 [doi]
PST - ppublish
SO  - Drug Chem Toxicol. 2021 Jan;44(1):92-100. doi: 10.1080/01480545.2018.1560466. 
      Epub 2019 May 31.